An intravenous programmed death ligand 1 checkpoint inhibitor for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, and for patients who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
If you have a Hayes login, click here to view the full report on the Knowledge Center.